Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBITDA (2016 - 2025)

Veracyte's EBITDA history spans 14 years, with the latest figure at $37.2 million for Q4 2025.

  • For Q4 2025, EBITDA rose 790.9% year-over-year to $37.2 million; the TTM value through Dec 2025 reached $57.8 million, up 257.93%, while the annual FY2025 figure was $57.8 million, 257.93% up from the prior year.
  • EBITDA for Q4 2025 was $37.2 million at Veracyte, up from $22.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $37.2 million in Q4 2025 and bottomed at -$41.9 million in Q1 2021.
  • The 5-year median for EBITDA is -$8.5 million (2021), against an average of -$6.6 million.
  • The largest annual shift saw EBITDA tumbled 555.11% in 2023 before it skyrocketed 790.9% in 2025.
  • A 5-year view of EBITDA shows it stood at -$12.3 million in 2021, then soared by 56.05% to -$5.4 million in 2022, then crashed by 555.11% to -$35.5 million in 2023, then surged by 111.76% to $4.2 million in 2024, then surged by 790.9% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's EBITDA are $37.2 million (Q4 2025), $22.9 million (Q3 2025), and -$5.3 million (Q2 2025).